BIOCRYST PHARMACEUTICALS INC (BCRX)       10.58  -0.2 (-1.86%)

Company Profile

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

Company Info

BIOCRYST PHARMACEUTICALS INC

4505 Emperor Blvd Ste 200

Durham NORTH CAROLINA 27703

P: 19198591302.0

CEO: Jon P. Stonehouse

Employees: 358

Website: https://www.biocryst.com/